You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Type 2 Issues Articles
Popular Type 2 Issues Articles
Highly Recommended Type 2 Issues Articles
Send a link to this page to your friends and colleagues.
The Food and Drug Administration has given Cadila Healthcare the go-ahead to conduct U.S. trials of its ZYGK1 drug for treating diabetes.
Cadila is a pharmaceutical company based in Ahmedabad, in India's Gujarat state. The firm does business in 90 countries.
ZYGK1 is an orally administered drug that acts as a glucose sensor in the pancreas and regulates glucose metabolism in the liver. It is considered a "new molecular entity," a chemical that has not been seen before in drugs. Because of its newness, an NME undergoes particularly intense scrutiny to prove its effectiveness and safety.
At this time, neither Cadila nor the FDA has given specifics about how the U.S. tests will proceed.
6 comments - May 6, 2011
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.